Faculty Collaboration Database

Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep 2014 Mar;9(1):57-65

Date

01/09/2014

Pubmed ID

24398726

Pubmed Central ID

PMC4031643

DOI

10.1007/s11899-013-0195-9

Scopus ID

2-s2.0-84896710555 (requires institutional sign-in at Scopus site)   12 Citations

Abstract

MDS are myeloid clonal hematologic disorders that are most commonly diagnosed in the seventh decade of life. Several treatment options are currently available. However, allo HSCT remains the only curative therapy. Unfortunately, despite the higher incidence of MDS in the older population, less than 10 % of patients undergoing allo HSCT for MDS are > 65 years old. In this paper we discuss the various treatment options in older patients with high-risk MDS with particular emphasis on the role of allo HSCT in older MDS patients.

Author List

Atallah E, Bylow K, Troy J, Saber W

Authors

Ehab L. Atallah MD Professor in the Medicine department at Medical College of Wisconsin
Kathryn A. Bylow MD Associate Professor in the Medicine department at Medical College of Wisconsin
Wael Saber MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Age Factors
Aged
Comorbidity
Hematopoietic Stem Cell Transplantation
Humans
Myelodysplastic Syndromes